about intraop medical co-founded in 1993 by dr. donald goer makers of the mobetron, the first fully...
TRANSCRIPT
About IntraOp Medical
• Co-founded in 1993 by Dr. Donald Goer
• Makers of the Mobetron, the first fully portable, self-shielding electron beam linear accelerator
• The Mobetron is used to administer intraoperative electron-beam radiation therapy (IOERT)
• 10 hospitals in North America have installed the Mobetron; 23 are in use worldwide
IOERT and Breast Cancer
• IOERT gaining traction as cutting-edge treatment for breast cancer patients around the world
• Dr. Umberto Veronesi, Director of the European Institute of Oncology in Milan, Italy and world-renowned breast surgeon, has pioneered the use of IOERT for this purpose
Dr. Umberto Veronesi – Background
• Dr. Veronesi has been a pioneering breast surgeon for nearly 40 years
• His clinical trials established breast conserving therapy – rather than mastectomy – as the standard of care for breast cancer patients
• His mission is to shift the breast cancer treatment paradigm from “maximum tolerable treatment” to “minimum effective treatment”
Dr. Umberto Veronesi – Current Study
• Dr. Veronesi’s research studies using IOERT for breast cancer began in 1999 and more than 3200 Italian women have taken part in it
• Dr. Veronesi’s current study seeks to determine whether women who receive breast-conserving surgery can have their post-surgical radiation reduced from the standard 6 weeks of daily radiation treatments to a 2-minute treatment of IOERT given at the time of surgery
• More than 1300 women have participated in this latest randomized trial
Study Results
• Dr. Veronesi presented the first findings of his randomized trial at the recent ISIORT conference in Madrid, Spain (June 2008)
• Patients were divided into two groups that received one of two types of treatment:– Breast conserving surgery and a single dose of IOERT– Breast conserving surgery and traditional 6 weeks of post-
operative radiation therapy
• Dr. Veronesi’s study reported that, to date, women who received a single dose of IOERT had identical control, survival and comestic results as those who underwent the standard 6 week radiation regimen
The Bombshell
A single dose of IOERT may be equivalent in outcome to 6 weeks of post-operative radiation therapy.
Many women can be successfully treated with IOERT rather than undergo a long course of radiation therapy.
What are the Benefits of Single-Dose IOERT?
• Single-dose radiation treatment means single-day treatment– Patients get back to their lives more quickly– Patients are spared the expense, time, and trouble of 6 weeks
of daily radiation– Patients can have oncoplastic reconstruction at the time of
surgery rather than have to return many months later for a second surgery
• IOERT gives doctors an edge on treating cancer– Doctors can apply radiation to the exact area that requires
treatment, avoiding healthy tissue– Doctors don’t have to wait until a patient heals to deliver life-
saving radiation
Where Can Breast Cancer Patients Receive Single-Dose IOERT Treatment?
• Single-dose IOERT treatment for breast cancer is widely available in Europe and Asia
• There is only one facility in the United States that offers single-dose IOERT breast cancer treatment
• The University of North Carolina Lineberger Comprehensive Cancer Center uses IntraOp’s Mobetron to administer single-dose IOERT to breast cancer patients
Why Aren’t More American Hospitals Offering IOERT Treatment?
• Cost– American hospitals do not want to pay for additional devices that
they are not certain they will quickly “break even” on– American hospitals are not certain insurance companies will
cover the treatment – sufficiently, or at all
• Knowledge– Many American doctors have been waiting for the results of the
Veronesi randomized trials before considering adopting this technique
• Availability– IOERT equipment is not yet widely available in the United States
Available for Comment
As manufacturers of the only machine in the United States capable of delivering single-dose IOERT to breast cancer patients, IntraOp Medical is poised to answer questions and comment on Dr. Veronesi’s recent findings.
IntraOp Medical’s founder, Dr. Donald Goer, as well as representatives from the University of North Carolina Lineberger Comprehensive Cancer Center, are available for comment. A patient who recently received single-dose IOERT from the Mobetron at UNC is also available for comment.
Spokespeople
• IntraOp Medical– Dr. Donald Goer, Founder and Chief Scientist– John Powers, CEO
• The University of North Carolina Lineberger Comprehensive Cancer Center– Dr. Joel Tepper, Professor and Chair of Radiation Oncology – Dr. David Ollila, Associate Professor and Surgical Director for
the Multidisciplinary Breast program and Multidisciplinary Melanoma Program
• Patient– Arleen Sharwell, single-dose IOERT breast cancer patient at the
University of North Carolina Lineberger Comprehensive Cancer Center
Additional Resources I
• Biographies– Dr. Donald Goer– Dr. Joel Tepper– Dr. David Ollila
• Case Study– Arleen Sharwell
• Video – Interview with Dr. Umberto Veronesi from the European Society
of Surgical Oncology meeting (2006)– Mobetron in use at the Ohio State University Comprehensive
Cancer Center
Additional Resources II
• Other documents– Single-dose treatment brochure– IOERT breast cancer brochure
– Nagoya University in Japan announces single-dose IOERT
treatment program for breast cancer patients
For More Information
Media Contact
Regina Nisita
Affect Strategies
212.398.9680 x145
Corporate Contact
Wink Jones
IntraOp Medical
303.447.1709